Plain-English translation of NCT05587205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of , a new medication injected directly into the eye during cataract surgery. The goal is to see whether this treatment is safe and tolerable in people who are having their cataracts removed and also have a low count of endothelial cells (the delicate cells that line the back of the cornea). Researchers want to understand whether the medication can help protect these cells and prevent vision problems after surgery.
Cataract surgery can sometimes damage the delicate endothelial cells on the back of the cornea, especially in people who already have fewer of these cells. This medication is being tested to see if it can protect these cells and potentially prevent corneal swelling or clouding that can happen after surgery.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have cataract surgery as you normally would. During the surgery, you will randomly receive either the new medication injected into your eye or a sham (fake) injection—neither you nor the surgeon will know which one you're getting. After surgery, you will have follow-up visits to check your eye health, vision, and how well you tolerate the treatment. The study involves about 32 people total.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
Mexico
Phase
Safety & dosing
Sponsor
Asociación para Evitar la Ceguera en México
Collaborators
Emmecell
Enrollment target
~32 participants
Started
August 2022
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yara Luna
Asociacion para Evitar la Ceguera
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.